A phase II study of carboplatin and etoposide plus durvalumab for previously untreated extensive-stage small-cell lung cancer (ES-SCLC) patients with a poor performance status (PS): NEJ045A study protocol

Peer Review reports

Original Submission
13 Dec 2021	Submitted	Original manuscript
7 Jul 2022	Reviewed	Reviewer Report
10 Jul 2022	Reviewed	Reviewer Report
26 Jul 2022	Author responded	Author comments - Tetsuhiko Asao
Resubmission - Version 2
26 Jul 2022	Submitted	Manuscript version 2
10 Aug 2022	Reviewed	Reviewer Report
12 Aug 2022	Reviewed	Reviewer Report
12 Sep 2022	Author responded	Author comments - Tetsuhiko Asao
Resubmission - Version 3
12 Sep 2022	Submitted	Manuscript version 3
Publishing
24 Oct 2022	Editorially accepted
4 Nov 2022	Article published	10.1186/s12885-022-10222-1

Back to article page